Ability of Rabeprazole to Prevent Gastric Mucosal Damage From Clopidogrel and Low Doses of Aspirin Depends on CYP2C19 Genotype

Clinical Gastroenterology and Hepatology

Volumn 10, Issue 8, 2012, Pages 879-885.e2

  Uotani, Takahiro ^a   Sugimoto, Mitsushige ^a   Nishino, Masafumi ^a   Kodaira, Chise ^a   Yamade, Mihoko ^a   Sahara, Shu ^a   Yamada, Takanori ^a   Osawa, Satoshi ^a   Sugimoto, Ken ^a   Tanaka, Tatsuo ^a   Umemura, Kazuo ^a   Watanabe, Hiroshi ^a   Miyajima, Hiroaki ^a   Furuta, Takahisa ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular; Drug interactions; PPI; Stomach

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DISEASE SEVERITY; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; GASTRIC PH MONITORING; GENOTYPE; HELICOBACTER PYLORI; HUMAN; JAPANESE; LOW DRUG DOSE; MALE; MODIFIED LANZA SCORE; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH MUCOSA INJURY; STOMACH ULCER; THROMBOCYTE FUNCTION;

EID: 84864103482     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.04.016     Document Type: Article

References (22)

1. Taha A.S., Angerson W.J., Knill-Jones R.P., et al. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs: a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2005, 22:285-289.
2. Nishino M., Sugimoto M., Kodaira C., et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011, 51:1079-1086.
3. Sugimoto M., Nishino M., Kodaira C., et al. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol 2010, 50:320-330.
4. Derry S., Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000, 321:1183-1187.
5. Sugimoto M., Nishino M., Kodaira C., et al. Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. Digestion 2011, 85:9-17.
6. Fork F.T., Lafolie P., Tóth E., et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers: a gastroscopic study. Scand J Gastroenterol 2000, 35:464-469.
7. Wikman Jorgensen P., Lopez Calleja E., Safont Gaso P., et al. Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev Espan Enferm Dig 2011, 103:360-365.
8. Bhatt D.L., Scheiman J., Abraham N.S., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008, 52:1502-1517.
9. Furuta T., Graham D.Y. Pharmacologic aspects of eradication therapy for Helicobacter pylori infection. Gastroenterol Clin North Am 2010, 39:465-480.
10. Simon T., Verstuyft C., Mary-Krause M., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
11. Sibbing D., Morath T., Stegherr J., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009, 101:714-719.
12. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363:1909-1917.
13. Lanza F.L., Chan F.K., Quigley E.M., et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009, 104:728-738.
14. Nishino M., Sugimoto M., Kodaira C., et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci 2010, 55:1627-1636.
15. Lanza F.L., Royer G.L., Nelson R.S., et al. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981, 75:17-21.
16. Naito Y., Yoshikawa T., Iinuma S., et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci 1998, 43:83S-89S.
17. Svedlund J., Sjödin I., Dotevall G. GSRS: a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988, 33:129-134.
18. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339. CAPRIE Steering Committee.
19. Chan F.K., Ching J.Y., Hung L.C., et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005, 352:238-244.
20. Sugimoto M., Furuta T., Shirai N., et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004, 76:290-301.
21. Yasuda S., Horai Y., Tomono Y., et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin Pharmacol Ther 1995, 58:143-154.
22. Furuta T., Shirai N., Takashima M., et al. Effect of genotypic differences in interleukin-1 beta on gastric acid secretion in Japanese patients infected with Helicobacter pylori. Am J Med 2002, 112:141-143.